The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.
Journal Title: Pharmacological Reports - Year 2005, Vol 57, Issue
Abstract
Prostanoids act leading roles in a myriad of physiologic and pathologic processes because these autacoids participate in the amplification of biological responses induced by innumerable stimuli. The formation of prostanoids is operated by two synthases named cyclooxygenase (COX)-1and COX-2. Traditional nonsteroidal antiinflammatory drugs (tNSAIDs) and COX-2 inhibitors (coxibs) giverise to antipyretic, analgesic, and antiinflammatory actions, through their reversible clogging of the COX channel of COX-2 - apart from aspirin which modifies irreversibly the catalytic activity of COX-2. tNSAIDs and COX-2 inhibitors resulted clinically equivalent for the relief of acute pain and symptoms of arthropathies but they failed to modify disease progression. Clinical evidence of the possible contribution of COX-1 in inflammation and pain in some occasion - as suggested by experimental and pharmacology studies- is orphan because none efficacy trial with COX inhibitors was designed to establish it. COX-2 inhibitors were developed with the aim to reduce the incidence of serious gastrointestinal (GI) adverse effects associated with the administration of tNSAIDs ensued as a consequence of the inhibition of cytoprotective COX-1-derived prostanoids. However, the reduced incidence of serious GI adverse effects compared to tNSAIDs demonstrated for 2 COX-2 inhibitors (e.g. rofecoxib and lumiracoxib) has been countered by an increased incidence of myocardial infarction and stroke detected in 5 placebo controlled trials involving the COX-2 inhibitors celecoxib, rofecoxib and valdecoxib. The future of COX-2 inhibitors will be an example of personalised medicine as their use will be restricted to patients who do not respond to tNSAIDs or with increased risk of GI complications.
Authors and Affiliations
Maria Sciulli, Marta Capone, Stefania Tacconelli, Paola Patrignani
Keywords
Related Articles
- EP ID EP107376
- DOI -
- Views 119
- Downloads 0
Effect of resveratrol on scopolamine-induced cognitive impairment in mice.
Background: Resveratrol (3,4',5-trihydroxystilbene) is a naturally occurring compound found in grapes, wine, peanuts and cranberries. Recently, in vitro and cell culture studies have reported beneficial effects of resver...
Toxicity of pyrimidine derivatives under oxidative stress conditions: chemiluminescence-based assays in systems containing erythrocytes, mitochondria or blood plasma.
Participation of mono-, di-, and tricyclic pyrimidine derivatives in free radical processes was investigated with the use of luminol-enhanced chemiluminescence in measurements performed in vitro in systems containing ery...
Strontium ranelate treatment improves oxidative damage in osteoporotic rat model.
Background: Osteoporosis is the most common skeletal disorder and is considered a risk of fracture. Most medication used for the treatment of osteoporosis is antiresorptive; however, strontium ranelate (Sr) therapy in po...
Impact of postnatal dexamethasone on psychotomimetic effects of MK-801 measured on adult rats.
The present study investigates the impact of dexamethasone (DEX) given in tapering doses in the postnatal period on MK-801-induced locomotor activity and MK-801-evoked deficits of sensorimotor gating of adult rats (60 da...
Simvastatin inhibits the increase in serum tau protein levels in the acute phase of ischemic stroke.
Our goal was to analyze the effects of treatment with a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (simvastatin, 40 mg/day) on serum S100BB and tau protein levels during the acute ischemic stroke...